Interparfums Stock: Rebound After Publishing Mixed Annual Results
Interparfums stock has risen by 2.47% this Thursday, February 26, reaching 24.90 euros, following the announcement of its annual results for 2025. The company, which specializes in licensed fragrances, reported increased revenues but a slight decline in net profit, amid ongoing technical fragility in the stock.
Annual Financial Overview
Interparfums unveiled its annual financial statements on February 25. The company reported revenues of 899.4 million euros for the fiscal year 2025, a 2% increase year-over-year. This modest growth contrasts with the dynamism seen in previous years. Meanwhile, the net profit attributable to the group decreased by 3%, to 126.6 million euros, indicating a profitability erosion despite the increase in activity. The financial calendar schedules the publication of the first quarter 2026 revenues on April 22, followed by the general assembly two days later. These events will assess the group's trajectory at the start of the fiscal year and provide insights into strategic outlooks, particularly concerning the portfolio of licenses and international dynamics.
Current Stock Performance
Despite the rebound recorded this Thursday, Interparfums' stock price remains significantly below its 200-day moving average of 29.75 euros, indicating a persistent bearish trend. The gap with the 50-day moving average, which is at 25.26 euros, is narrowing but not yet closed, with the stock still trading below this threshold. The Relative Strength Index (RSI) stands at 33, close to the oversold zone, which typically signals excessive selling pressure on the stock. Over the past year, the stock has declined by 35.85%, highlighting the extent of the correction it has undergone. The most immediate technical support is at 23.98 euros, a floor that was recently tested, while the nearest resistance is at 26.44 euros. The stock is currently moving within a relatively narrow range between these two levels, where today's session marks a catch-up movement after several tentative sessions.